ProCE Banner Activity

ORAL Shift: Withdrawal of Methotrexate in Patients With Rheumatoid Arthritis Who Achieved Low Disease Activity With Tofacitinib Plus Methotrexate

Slideset Download
Conference Coverage
Tofacitinib monotherapy after methotrexate withdrawal does not worsen disease activity in RA patients who previously achieved low disease activity with tofacitinib plus methotrexate.

Released: June 18, 2019

Expiration: June 16, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Lilly

Sanofi Genzyme and Regeneron Pharmaceuticals